Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Sees Significant Growth in Short Interest

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) saw a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 7,780,000 shares, an increase of 94.5% from the December 15th total of 4,000,000 shares. Based on an average daily volume of 100,730,000 shares, the days-to-cover ratio is presently 0.1 days. Currently, 4.2% of the shares of the company are sold short.

Tonix Pharmaceuticals Stock Performance

Shares of TNXP traded up $0.01 on Wednesday, reaching $0.23. 65,830,587 shares of the stock traded hands, compared to its average volume of 67,687,922. The firm has a market cap of $43.42 million, a price-to-earnings ratio of 0.00 and a beta of 2.02. Tonix Pharmaceuticals has a 12 month low of $0.12 and a 12 month high of $12.48. The stock’s 50-day moving average price is $0.25 and its 200-day moving average price is $0.31. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.03) by $1.80. The firm had revenue of $2.82 million for the quarter, compared to analyst estimates of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. Equities analysts forecast that Tonix Pharmaceuticals will post -17.63 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, StockNews.com began coverage on shares of Tonix Pharmaceuticals in a research note on Thursday, January 9th. They issued a “hold” rating for the company.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.